NARA Discovery
Article Details
← Back to Search Results
Journal Article

Effect of use of NSAIDs or steroids during the acute phase of pain on the incidence of chronic pain: a systematic review and meta-analysis of randomised trials

Luyao Huo; Gang Liu; Bowen Deng; Lin Xu; Yanjun Mo; Shengyuan Jiang; Jingwei Tao; Huizhong Bai; Li Wang; Xiaoxiao Yang; Jizhou Yang; Xiaohong Mu
Inflammopharmacology · Vol. 32, Issue 2 · pp. 1039-1058 · 2024

Abstract

Background This study is the first to summarize the evidence on how the use of anti-inflammatory drugs during acute pain has an impact on the development of chronic pain. Methods Randomized controlled trials retrieved from nine databases included anti-inflammatory drugs (NSAIDs or steroids) versus non-anti-inflammatory drugs in patients with acute pain and reported the incidence of chronic pain. No specified date, age, sex, or language restrictions. Subgroup analyses were performed according to pain classification, follow-up time, and medication. The GRADE method was used to evaluate quality of evidence. Results A total of 29 trials (5220 patients) were included. Steroids or NSAIDs did not reduce the incidence of chronic nociceptive pain. Steroid use in acute phase significantly reduced the incidence of chronic neuropathic pain. In subgroup analysis, benefits were observed for methylprednisolone and dexamethasone, with some adverse effects. Steroids or NSAIDs were statistically significant in reducing pain intensity over 1 year, but the effect size was too small, and whether the long-term effect is clinically relevant needs to be further studied. Conclusion Quality of the evidence was low to moderate. No drug can be recommended to prevent chronic nociceptive pain. Injections of steroids (methylprednisolone or dexamethasone) during the acute phase reduce the incidence of chronic neuropathic pain, but most included studies also used local anesthetics. The results are indirect and need to be interpreted with caution. The pooled data effect sizes for pain intensity were small, so the clinical relevance was unclear. Study registration PROSPERO (CRD42022367030).

Bibliographic Information

JournalInflammopharmacology
PublisherSpringer
Publication Date2024-04-01
Publication Year2024
Volume32
Issue2
Pages1039-1058
Document TypeJournal Article
Print ISSN0925-4692
eISSN1568-5608
DOI10.1007/s10787-023-01405-8

Access Information

NARA Access Coverage1991-01-01~Current
Journal Homepagehttps://www.springer.com/journal/10787
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.